Development of the Antileishmanial Vaccine
Sunil Kumar1, Shubhranshu Zutshi1, Mukesh Kumar Jha1,2
1National Centre for Cell Science, Ganeshkhind, Pune, Maharashtra, India.
Methods in Molecular Biology (Clifton, N.J.)
|December 16, 2021
Summary
Developing an effective antileishmanial vaccine remains challenging, prompting research into new vaccine types and assessment methods. This chapter reviews historical efforts, formulation techniques, and efficacy evaluations for leishmaniasis vaccine candidates.
Area of Science:
- Parasitology
- Vaccinology
- Immunology
Background:
- Despite decades of research, no effective antileishmanial vaccine has reached clinical success.
- Leishmaniasis remains a significant global health concern, necessitating novel vaccine strategies.
Purpose of the Study:
- To provide a comprehensive overview of antileishmanial vaccine development.
- To discuss historical vaccine research, formulation techniques, and assessment methodologies.
Main Methods:
- Review of historical antileishmanial vaccine development timelines.
- Analysis of techniques for whole-parasite and subunit vaccine formulation.
- Examination of immunogenicity and protective efficacy assessment methods.
Main Results:
- No vaccine candidate has yet proven sufficiently efficacious in clinical trials.
- Ongoing research focuses on novel vaccine modalities and improved assessment techniques.
Conclusions:
- Antileishmanial vaccine development requires innovative approaches.
- Further advancements in vaccine formulation and rigorous efficacy testing are crucial for future success.
Keywords:
Antileishmanial vaccineElectroporationFlow cytometryImmunogenicityMass spectrometryNi-NTA affinity chromatographyParasite loadT-helper responseMore Related Videos
Related Concept Videos
01:51Vaccinations
Overview
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...